Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Purchases 7,803 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 7,803 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was purchased at an average price of $24.25 per share, with a total value of $189,222.75. Following the completion of the purchase, the chief financial officer owned 41,688 shares in the company, valued at approximately $1,010,934. This trade represents a 23.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sensei Biotherapeutics Stock Performance

FTH stock traded down $1.34 during midday trading on Wednesday, hitting $23.66. 114,325 shares of the stock traded hands, compared to its average volume of 89,623. Sensei Biotherapeutics, Inc. has a 1-year low of $6.32 and a 1-year high of $36.76.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on FTH shares. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Weiss Ratings started coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Finally, Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.